Literature DB >> 18522978

Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.

S Leboulleux1, C Dromain, A L Vataire, D Malka, A Aupérin, J Lumbroso, P Duvillard, D Elias, D M Hartl, T De Baere, J Guigay, M Schlumberger, M Ducreux, E Baudin.   

Abstract

PURPOSE: Our purpose was to compare the sensitivity of whole body (WB) magnetic resonance imaging (MRI) and somatostatin receptor scintigraphy (SRS) for the diagnosis of bone metastases (BMs) in patients with well-differentiated gastro-entero-pancreatic endocrine cancer (WD-GEP-EC) and to determine predictive factors of BM. PATIENTS AND METHODS: WB-MRI and SRS were prospectively performed in 79 patients with bronchial (11), thymic (five), gastric (two), duodeno-pancreatic (24), ileal (26), colic (one), or unknown primary (10) WD-GEP-EC.
RESULTS: A total of 36 patients (46%) had 333 BMs involving 119 skeletal segments. WB-MRI and SRS were equally sensitive for detecting patients with BM (86 vs. 81%; P = 0.56), with 33% of the patients diagnosed with only one procedure. WB-MRI detected more BMs than SRS (80 vs. 57%; P = 0.017). Compared with SRS, WB-MRI detected more spine BMs (96 vs. 45%; P < 0.001) and tended to detect more pelvic and lower limb BMs (P = 0.054 and P = 0.06, respectively). Compared with WB-MRI, SRS detected more skull BMs (100 vs. 0%; P < 0.001) and tended to detect more rib BMs (P = 0.08). Sternal and upper-limb BMs were equally detected with WB-MRI and SRS (P = 0.32 and P = 0.46, respectively). Bone staging with SRS and spine MRI rather than WB-MRI would have detected 92% of the patients with BMs and 83% of all BMs. The extent of liver involvement and bronchial-thymic primary tumors were independent predictive factors for BM.
CONCLUSIONS: We recommend bone staging with SRS and spine MRI in all patients with bronchial-thymic or unknown primary WD-GEP-EC. In case of duodeno-pancreatic or ileal primary, bone imaging may be restricted to patients with liver metastases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522978     DOI: 10.1210/jc.2008-0459

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.

Authors:  Talal Hilal
Journal:  Ther Adv Med Oncol       Date:  2016-11-17       Impact factor: 8.168

2.  Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.

Authors:  A Faggiano; P Ferolla; F Grimaldi; D Campana; M Manzoni; M V Davì; A Bianchi; R Valcavi; E Papini; D Giuffrida; D Ferone; G Fanciulli; G Arnaldi; G M Franchi; G Francia; G Fasola; L Crinò; A Pontecorvi; P Tomassetti; A Colao
Journal:  J Endocrinol Invest       Date:  2011-11-09       Impact factor: 4.256

Review 3.  The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons.

Authors:  Carlo Sposito; Michele Droz Dit Busset; Davide Citterio; Marco Bongini; Vincenzo Mazzaferro
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

4.  Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.

Authors:  Julien Hadoux; Marie Terroir; Sophie Leboulleux; Frederic Deschamps; Abir Al Ghuzlan; Ségolène Hescot; Lambros Tselikas; Isabelle Borget; Caroline Caramella; Desirée Déandréis; Diane Goere; Thierry De Baere; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2017-07-26       Impact factor: 3.869

5.  Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension.

Authors:  F Dumont; Y Goudard; C Caramella; D Goéré; E Baudin; D Elias
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

6.  Metabolic Bone Disease in the Context of Metastatic Neuroendocrine Tumor: Differentiation from Skeletal Metastasis, the Molecular PET-CT Imaging Features, and Exploring the Possible Etiopathologies Including Parathyroid Adenoma (MEN1) and Paraneoplastic Humoral Hypercalcemia of Malignancy Due to PTHrP Hypersecretion.

Authors:  Rohit Ranade; Sandip Basu
Journal:  World J Nucl Med       Date:  2017 Jan-Mar

7.  Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group.

Authors:  Rachel P Riechelmann; Rui F Weschenfelder; Frederico P Costa; Aline Chaves Andrade; Alessandro Bersch Osvaldt; Ana Rosa P Quidute; Allan Dos Santos; Ana Amélia O Hoff; Brenda Gumz; Carlos Buchpiguel; Bruno S Vilhena Pereira; Delmar Muniz Lourenço Junior; Duilio Reis da Rocha Filho; Eduardo Antunes Fonseca; Eduardo Linhares Riello Mello; Fabio Ferrari Makdissi; Fabio Luiz Waechter; Francisco Cesar Carnevale; George B Coura-Filho; Gustavo Andrade de Paulo; Gustavo Colagiovanni Girotto; João Evangelista Bezerra Neto; João Glasberg; Jose Claudio Casali-da-Rocha; Juliana Florinda M Rego; Luciana Rodrigues de Meirelles; Ludhmila Hajjar; Marcos Menezes; Marcello D Bronstein; Marcelo Tatit Sapienza; Maria Candida Barisson Villares Fragoso; Maria Adelaide Albergaria Pereira; Milton Barros; Nora Manoukian Forones; Paulo Cezar Galvão do Amaral; Raphael Salles Scortegagna de Medeiros; Raphael L C Araujo; Regis Otaviano França Bezerra; Renata D'Alpino Peixoto; Samuel Aguiar; Ulysses Ribeiro; Tulio Pfiffer; Paulo M Hoff; Anelisa K Coutinho
Journal:  Ecancermedicalscience       Date:  2017-01-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.